PubMed ID:
25468160
Public Release Type:
Journal
Publication Year: 2015
Affiliation: The National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
DOI:
https://doi.org/10.1016/S0140-6736(14)61933-4
Authors:
Hoofnagle JH,
Vuppalanchi R,
Kleiner DE,
Kleiner DE,
Terrault N,
Terrault N,
Terrault N,
Chalasani N,
Chalasani N,
Chalasani N,
Abdelmalek MF,
Abdelmalek MF,
Ackermann S,
Ang B,
Aouizerat B,
Atla P,
Barlow S,
Bashir M,
Bass NM,
Behling C,
Belt P,
Bhatt A,
Boyett S,
Brandman D,
Brown SR,
Brunt EM,
Brunt EM,
Buie S,
Carucci L,
Clark JM,
Clark JM,
Contos MJ,
Cooney S,
Coy D,
Croft B,
Cummings OW,
Dasarathy J,
Dasarathy S,
Dasarathy S,
Dasarathy S,
Diehl AM,
Diehl AM,
Diehl AM,
Donithan M,
Doo E,
Doo E,
Doo EC,
Ferrell LD,
Fowler K,
Garcia R,
Garcia S,
Gawrieh S,
Gelinas K,
Ghabril M,
Gill R,
Guy C,
Hallinan E,
Hameed B,
Hameed B,
Hawkins C,
Isaacson M,
Kigongo C,
King D,
Kowdley K,
Kowdley KV,
Kowdley KV,
Kraft K,
Lavine J,
Lavine J,
Lavine JE,
Lee M,
Loomba R,
Loomba R,
Loomba R,
Luketic VA,
Marri S,
May KP,
McCullough A,
McCullough A,
McCullough AJ,
McCullough AJ,
Middleton M,
Miriel L,
Molleston J,
Mooney J,
Murray K,
NASH Clinical Research Network,
Nelson JE,
Neuschwander-Tetri B,
Neuschwander-Tetri BA,
Neuschwander-Tetri BA,
Osmack P,
Pagadala M,
Pai R,
Pan YP,
Patton H,
Pierce T,
Piercy D,
Puri P,
Ragozzino L,
Ramos C,
Robuck PR,
Rosenthal P,
Sandrasegaran K,
Sanyal A,
Sanyal AJ,
Sanyal AJ,
Sargent R,
Schlosser J,
Schwimmer J,
Shaw C,
Sheikh M,
Sherker A,
Siddique A,
Siddiqui MS,
Siegner J,
Singh M,
Sirlin C,
Sirlin C,
Sternberg A,
Stewart S,
Tonascia J,
Tonascia J,
Tonascia J,
Torrance RJ,
Torretta S,
Ünalp-Arida A,
Ungermann A,
Van Natta M,
Van Natta ML,
Vaughn I,
Wang C,
Whitington P,
Wilson L,
Wolford B,
Xanthakos S,
Yates K
Studies:
Nonalcoholic Steatohepatitis Clinical Research Network
,
The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment
The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of obeticholic acid in adult patients with non-alcoholic steatohepatitis.